Market Cap (In USD)
16.87 Million
Revenue (In USD)
10 Thousand
Net Income (In USD)
-36.89 Million
Avg. Volume
1.43 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.14-3.53
- PE
- -0.44
- EPS
- -0.59
- Beta Value
- 1.842
- ISIN
- US38000Q1022
- CUSIP
- 38000Q102
- CIK
- 1253689
- Shares
- 64513900.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Harout Semerjian
- Employee Count
- -
- Website
- https://www.glycomimetics.com
- Ipo Date
- 2014-01-10
- Details
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
More Stocks
-
TMIP
-
BITE
-
GLHRL
-
TSLX
-
JBHIFJB Hi-Fi Limited
JBHIF
-
MVV1MVV Energie AG
MVV1
-
M44U
-
ADVPETR-BAdvance Petrochemicals Limited
ADVPETR-B